STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
Navin R PintoCatherine M AlbertMallory R TaylorHeidi B UllomAshley Lauren WilsonWenjun HuangJason P WendlerSowmya PattabhiKristy SeidelChristopher BrownJoshua A GustafsonStephanie D Rawlings-RheaSafia H E CheeneyKatelyn BurleighHeather H GustafsonRimas J OrentasNicholas A VitanzaRebecca A GardnerMichael C JensenJulie R ParkPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
B7-H3 CAR T cells are tolerable and demonstrate limited antitumor activity without acute on-target, off-tumor toxicity. High levels of CAR T cell expansion may be necessary to achieve objective responses, but undefined host and tumor microenvironment factors appear to be critical (ClinicalTrials.gov identifier: NCT04483778).